Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

NCT04607408 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

NETWORK

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: CH505TF gp120
BIOLOGICAL: GLA-SE adjuvant
BIOLOGICAL: Placebo

Sponsor

HIV Vaccine Trials Network

Collaborators

[object Object]